Compare TENX & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | EVC |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8M | 335.0M |
| IPO Year | 2001 | 2000 |
| Metric | TENX | EVC |
|---|---|---|
| Price | $15.72 | $10.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.35% |
| EPS Growth | N/A | ★ 47.59 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $536,034,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $84.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.80 | $1.95 |
| 52 Week High | $19.40 | $13.74 |
| Indicator | TENX | EVC |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 49.16 |
| Support Level | $12.84 | $2.75 |
| Resistance Level | $16.35 | $13.74 |
| Average True Range (ATR) | 1.28 | 0.80 |
| MACD | -0.17 | -0.30 |
| Stochastic Oscillator | 36.73 | 20.33 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.